One vision —
a cancer-free future.
Unlike surgery, chemotherapy and radiation, cell and gene therapies harness the power of your immune system to destroy cancer cells without harming healthy tissue. We fund the research that will make this vision a reality.
Cell and gene therapy for brain cancer: What ACGT is doing to advance research
This year for Brain Cancer Awareness Month, ACGT is leading the #FightForTheBrain by raising awareness of cell and gene therapy for brain cancer.
ACGT Awards Luncheon honors Dr. Mackall, features keynote from Dr. Mukherjee
The ACGT Awards Luncheon celebrated the 20th anniversary of the non-profit organization and ushered in a new era of advancing cell and gene therapy science.
ACGT Summit 2023 provides ‘vital’ collaboration event for scientists
Summit 2023 was a day-long, invitation-only event bringing together top scientists in the field of cancer cell and gene therapy.
Oncolytic virus therapy: How viruses can kill tumor cells
ACGT has funded research programs using oncolytic virus therapy for solid tumors like glioblastoma, breast cancer and more.
Our direct impact on eradicating all cancer.
Collaborating with partners and funding research fellows, we are transforming cancer treatments today while bringing the world closer to a cure for all cancers tomorrow.
34.2
million dollars awarded to groundbreaking research.
63
research fellows awarded grants.
38
top medical institutions funded.
Join forces with the world’s leading researchers to finally identify cures.
Cell and gene therapies harness the power of a patient’s own immune system to destroy cancer cells without harming healthy tissue.
Hideho Okada, MD, PhD
University of California San Francisco
ACGT is funding a new clinical trial for children with a rare brain cancer.
Crystal Mackall, MD
Stanford University
Training CAR T cells to find and kill cancers that express the GD2 biomarker, including osteosarcoma, pediatric neuroblastoma and diffuse intrinsic pontine glioma.
Stephen Gottschalk, MD
St. Jude Children’s Research Hospital
Fortifying a patient’s immune system to attack and destroy sarcomas along with the blood vessels that support their growth.
Brian Brown, PhD
Icahn School of Medicine at Mount Sinai
Working to harness the power of gene therapy to equip a patient’s own T cells to kill immune-suppressing cells.
Hideho Okada, MD, PhD
University of California San Francisco
ACGT is funding a new clinical trial for children with a rare brain cancer.
Crystal Mackall, MD
Stanford University
Training CAR T cells to find and kill cancers that express the GD2 biomarker, including osteosarcoma, pediatric neuroblastoma and diffuse intrinsic pontine glioma.
Stephen Gottschalk, MD
St. Jude Children’s Research Hospital
Fortifying a patient’s immune system to attack and destroy sarcomas along with the blood vessels that support their growth.
Brian Brown, PhD
Icahn School of Medicine at Mount Sinai
Working to harness the power of gene therapy to equip a patient’s own T cells to kill immune-suppressing cells.
Stay up-to-date with us and get involved.
Oct 05, 2022
100% of your donation will advance research to cure all cancers.
Your donation will help develop radical new cell and gene therapies that leverage the body’s own biology and immune system to control and ultimately eradicate cancer. 100% of donations directly support scientists working on breakthrough cancer cell and gene therapy research.
Donate Today